Clinigen Group is a global specialty pharmaceutical and services business focused on improving patient access to treatments for unmet medical needs. The company operates two core divisions: Branded Pharmaceuticals, which develops and commercializes repurposed medicines across oncology, rare diseases and other specialty therapy areas, and Services, which provides clinical trial supply, commercial logistics and named-patient access programs. By combining these capabilities, Clinigen aims to extend the lifecycle of established therapies while supporting the efficient delivery of investigational and off-label medicines.
The Branded Pharmaceuticals division manages a portfolio of therapies that address supportive care in cancer treatment as well as treatments for rare and orphan conditions. Through life cycle management and regulatory expertise, Clinigen secures approvals in multiple jurisdictions to bring these repurposed treatments to new patient populations. The Services division offers end-to-end solutions for pharmaceutical and biotech companies, including packaging, distribution and supply-chain management for clinical trials, compassionate use programs and import/export logistics.
Headquartered in the United Kingdom, Clinigen Group serves customers across North America, Europe, Asia-Pacific and other emerging markets. The company has established a network of facilities and partnerships to ensure continuity of supply and regulatory compliance in over 80 countries. This global footprint supports both the commercialization of branded products and the operational demands of complex clinical development programs.
Clinigen’s management team, led by Chief Executive Officer Paul Groves, brings deep experience in specialty pharmaceuticals, regulatory affairs and global supply-chain operations. Since its listing on the London Stock Exchange, the company has grown through a combination of strategic acquisitions and organic expansion, reinforcing its position in specialty therapies and service offerings that bridge the gap between clinical innovation and patient access.
AI Generated. May Contain Errors.
